$DIN

Dine Brands Global Q2 Earnings Call Highlights

Dine Brands Global (NYSE:DIN) reported Q2 earnings call highlights. Management cited inflation in food-away-from-home, higher gasoline prices, and weaker consumer sentiment, while average check rose slightly at Applebee’s and IHOP. Value offers were 26% of Applebee’s sales mix and 22% at IHOP. Off-premise comps rose 1.5% (Applebee’s) and 3.5% (IHOP). Adjusted free cash flow was $3.7M for six months; $9M returned to shareholders in Q2, and a $100M repurchase authorization was added.

Original reporting
Published Aug 6, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dine Brands Global Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$DINNeutralMed
01

Why it matters

Traders can use the quantified comps (off-premise and catering) and cash-flow/capex figures to update short-term expectations for restaurant-level momentum versus near-term free-cash-flow pressure from remodels and conversions.

02

Market read

Operating momentum appears supported by value offerings and off-premise growth, while elevated capex and incentives reduced adjusted free cash flow year over year.

03

What to watch

The article cites positive sales lift from remodels and promotional periods, but does not quantify full-year guidance or margin trajectory, leaving uncertainty around profitability after higher capex and incentives.

Relevance 6/10Novelty 5/10Timing: post-Q2 earnings call highlights, positioning for near-term read-through

Background

The piece summarizes management commentary from Dine Brands Global’s Q2 earnings call, focusing on demand drivers, menu/value strategy, dual-brand expansion, and cash flow/capex.

Company-level read

Ticker impact

$DINNeutralMedium confidence
Context

Dine Brands reported Q2 call highlights including adjusted free cash flow of $3.7M, capex of $23.2M, and ongoing dual-brand expansion targets to 80 by year-end.

Expected impact

Near-term sentiment likely mixed: operating momentum (off-premise, value mix, remodel sales lift) offsets cash-flow pressure from elevated capex and incentives.

Evidence & confidence

The article provides multiple quantified operating and cash-flow datapoints (off-premise comps, catering growth, capex, adjusted FCF, cash balance) that can inform positioning, but it is a call-highlight recap rather than a fresh earnings release with full guidance details.

Market effects

Casual dining read-through: value mix stability and off-premise growth can support sector multiples, while capex intensity can pressure near-term free-cash-flow expectations.

No specific regional impact disclosed beyond domestic dual-brand footprint and company-owned portfolio.

Limited global relevance; discussion is primarily US restaurant operations and franchising economics.

Counterpoint

Cash-flow deterioration may be more structural than temporary if remodel and dual-brand conversion costs keep rising faster than incremental sales lift.

Key entities

  • Dine Brands Global, Inc.

    Franchisor and operator of Applebee’s and IHOP; discussed Q2 operating trends, dual-brand expansion, and cash flow/capex.

  • Applebee’s

    Highlighted promotions, liquor comp growth during promotional period, and remodel activity.

  • IHOP

    Highlighted value menu mix, limited-time pancake offer exceeding forecast, and off-premise/catering comp growth.

Related articles

$DINMed

Dine Brands (DIN) Q2 2026 Earnings Call Transcript

Dine Brands Global (DIN) reported Q2 2026 revenue of $240.9 million, up 4.4% year over year, driven mainly by acquiring restaurants from franchisees. Adjusted EBITDA fell to $54.2 million and adjusted diluted EPS was $1.16. IHOP domestic comps rose 1.5%, Applebee’s fell 1.8%. Management maintained full-year 2026 guidance.

$DINMed

Dine Brands Global, Inc. Q2 2026 Earnings Call Summary

Dine Brands Global (Applebee’s, IHOP) reported Q2 2026 call updates: management cited intentional consumer spending amid inflation and maintained full-year guidance. Applebee’s saw sequential improvement after a weak April, with remodels lifting mid-single-digit sales. IHOP beat traffic benchmarks for a third quarter. Adjusted FCF fell to $3.7M in H1; $100M buyback authorized.

$DINMed

Dine Brands Global, Inc. (DIN): Results of Operations and Financial Condition

Dine Brands Global, Inc. (DIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d148591dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Investor Contact Matt Lee Sr. Vice President, Finance and Investor Relations Dine Brands Global, Inc. IR@dinebrands.com Media Contact Susan Nelson Sr. Vice President, Global Communications Dine Brands Global, I

$ORGOMed

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.

$CRWVMed

CoreWeave Stock Buy or Sell Debate Intensifies in 2026 After Q2 Beat and $104 Billion Backlog

CoreWeave Inc. shares closed at $105.26 on Aug. 14, 2026 after its Q2 results. Revenue rose to $2.58B from $1.21B a year earlier; adjusted operating income was $128M, but GAAP net loss widened to $626M due to higher interest expense. The company raised 2026 revenue guidance to $12.4B-$13.2B and projected adjusted operating income of $960M-$1.15B. Backlog was about $104B.

$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.